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Belgian Fabry Study
Prevalence of Fabry Disease in a Cohort of 1000 Young Patients With
Cerebrovascular Disease
Raf Brouns, MD, PhD; Vincent Thijs, MD, PhD; Franc¸ois Eyskens, MD, PhD;
Marleen Van den Broeck, BSc; Shibeshih Belachew, MD, PhD; Christine Van Broeckhoven, PhD, DSc;
Patricia Redondo, MD, PhD; Dimitri Hemelsoet, MD; Arnaud Fumal, MD, PhD;
Sandrine Jeangette, MD, PhD; Werner Verslegers, MD; Robert Baker, BSc, MSc AIB, MS;
Derralynn Hughes, MD, PhD; Peter Paul De Deyn, MD, PhD; for the BeFaS Investigators*
Background and Purpose—Data on the prevalence of Fabry disease in patients with central nervous system pathology are
limited and controversial. In this study, we assessed the prevalence of Fabry disease in young patients presenting with
cerebrovascular disease in Belgium.
Methods—In this national, prospective, multicenter study, we screened for Fabry disease in 1000 patients presenting with
ischemic stroke, transient ischemic attack, or intracranial hemorrhage; unexplained white matter lesions; or vertebro-
basilar dolichoectasia. In male patients, we measured !-galactosidase A (!-GAL A) activity in dried blood spots.
Female patients were screened for mutations by exonic DNA sequencing of the !-GAL A gene.
Results—!-GAL A activity was deficient in 19 men (3.5%), although all had normal !-GAL A gene sequences. Enzymatic
deficiency was confirmed on repeat assessment in 2 male patients (0.4%). We identified missense mutations in 8 unrelated
female patients (1.8%): Asp313Tyr (n!5), Ala143Thr (n!2), and Ser126Gly (n!1). The pathogenicity of the 2 former
missense mutations is controversial. Ser126Gly is a novel mutation that can be linked to late-onset Fabry disease.
Conclusion—!-GAL A deficiency may play a role in up to 1% of young patients presenting with cerebrovascular disease.
These findings suggest that atypical variants of Fabry disease with late-onset cerebrovascular disease exist, although the
clinical relevance is unclear in all cases. (Stroke. 2010;41:863-868.)
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Fabry disease (Anderson-Fabry disease; Online MendelianInheritance in Man No. 301500) is an X-linked lysosomal
storage disorder caused by mutations in the !-galactosidase A
(!-GAL A) gene (GLA), leading to !-GAL A deficiencies.1
Consequently, neutral glycosphingolipids accumulate in
many tissues and cell types, including the vascular epithe-
lium, cornea, kidneys, and heart. Male hemizygotes are
generally more severely affected than are heterozygous fe-
males, but disabling clinical features and disease progression
often also occur in female patients.2 Patients with the classic
phenotype of Fabry disease usually present in childhood with
pain crises, acroparesthesia, hypohidrosis, gastrointestinal
symptoms, angiokeratoma, and corneal abnormalities. Severe
morbidity and mortality follow in adult life due to renal
failure, cardiac involvement, and stroke.3 Atypical variants
with late-onset manifestations in the cardiac, neurologic, and
renal systems have been described.4–13
Estimates on the prevalence of classic Fabry disease vary
from 1 in 40 000 to 1 in 117 000.14 Given the nonspecific
presenting symptoms and delayed presentation, atypical vari-
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ants of Fabry disease might be underdiagnosed.15 Epidemio-
logic studies have reported the condition in 0.2% to 1.2% of
patients with end-stage renal disease4–8 and in 1% to 6.3% of
patients with unexplained hypertrophic cardiomyopathy.9–11
The prevalence of Fabry disease in young patients with
cryptogenic stroke was reported to be as high as 4.9% in men
and 2.4% in women.13 This finding, however, was not
reproduced in a smaller, retrospective study.16 White matter
lesions and vertebrobasilar dolichoectasia are commonly
found in patients with Fabry disease,17 but literature data on
the prevalence of Fabry disease in patients with these neuro-
imaging findings are nonexistent.
The aim of the Belgian Fabry Study (BeFaS) was to
prospectively assess the frequency of Fabry disease in young
Belgian patients with neurologic hallmarks of this disease,




Thirty-three clinical neurology departments throughout Belgium
participated in this national, prospective, multicenter study, BeFaS.
From March 2007 to October 2008, 1000 patients aged 18 to 60
years, consecutively presenting at a participating neurology depart-
ment with stroke (ischemic stroke, transient ischemic attack, or
intracranial hemorrhage), unexplained white matter lesions, or ver-
tebrobasilar dolichoectasia were enrolled. Unexplained white matter
lesions were defined as the presence of lesions in the deep or
subcortical white matter on magnetic resonance imaging or com-
puted tomography for which no etiology was found after expert
neurologist evaluation. Patients who were unable to provide in-
formed consent, who were already diagnosed with Fabry disease, or
in whom this disease was previously excluded by appropriate
enzymatic or genetic analyses were excluded from participation in
BeFaS. The study was conducted in accordance with the revised
Declaration of Helsinki (1998) and in agreement with the guidelines
of the ethics committees of ZNA Antwerp, the University of
Antwerp, and the ethics committees of each of the participating
clinical neurologic centers.
After informed consent was obtained, demographic data, cardio-
vascular risk factors, presence of signs and symptoms of Fabry
disease, and clinical and neuroimaging data were registered in a
database by using web-based case report forms. Assessment of
clinical signs suggestive of Fabry disease was optional. Diagnosis or
exclusion of cornea verticillata was performed by ophthalmologists,
screening for angiokeratoma was done by routine clinical examina-
tion, and presence of acroparesthesia was obtained by anamnesis.
This symptom was regarded to be present if a history of burning or
tingling sensation in the extremities was reported by the patient or a
proxy.
Enzymatic and Genetic Testing
A blood sample was obtained for production of blood spots for
measurement of !-GAL A activity in male patients and for genetic
analyses of GAL in female patients, as described previously.18 In
men, screening for Fabry disease can reliably be performed by
enzymatic analysis, but this technique is affected by a high risk of
false-negative results in women. Genetic testing therefore is the
method of choice in the latter.2 All diagnostic tests were performed
blinded to case identity. Male patients with abnormal enzymatic
activity ("3.0 ng/h per mL) were additionally examined by gene
sequencing and repeat analysis of !-GAL A activity in a subset of
patients. In female patients with an abnormal result on gene
sequencing, repeat gene sequencing was performed.
Statistical Analysis
Data were analyzed with the use of Microsoft Excel (version 2007;
Microsoft Corp, Redmond, Wash) and the SPSS 15.0 software
package for Windows (SPSS Inc, Chicago, Ill). The 2-tailed unpaired
t test was used to compare continuous variables between 2 groups. A
1-way ANOVA was applied for comparison of continuous variables
when there were #2 groups, and the "2 test was used for noncon-
tinuous variables.
Role of the Funding Source
The sponsor of the study had no role in the study design, data
collection, data analysis, data interpretation, or the writing of the
report. The corresponding author had full access to all data and had
final responsibility for the decision to submit for publication.
Results
Clinical Data
The mean age ($SD) in the cohort of 1000 patients partici-
pating in BeFaS was 47.7$9.1 years, and 547 participants
(54.7%) were male. Magnetic resonance imaging of the brain
was obtained in 80.2% of patients. Cerebral computed tomog-
raphy was performed in the remaining patients. Classic
cerebrovascular risk factors, including arterial hypertension,
diabetes mellitus, dyslipidemia, smoking, and coronary dis-
ease, were present in 38.7%, 9.7%, 38.2%, 55.9%, and 7.6%
of patients, respectively. In 16.3% and 4.4% of participants, a
history of previous stroke or renal disease was found. Family
history for stroke, myocardial infarction before the age of 60
years, and dialysis was present in 19.7%, 13.0%, and 1.3%.
Clinical signs suggestive of Fabry disease were reported in a
minority of patients: cornea verticillata was found in 0.1%
and angiokeratoma in 0.9%. Dyshidrosis, episodic pain, and
acroparesthesia were reported by 4.6%, 7.0%, and 13.3% of
patients. Evidence of hypertrophic cardiomyopathy was
found on echocardiography in 12.0%. White matter lesions
were found in 35.0% of patients.
The main clinical criterion for inclusion in BeFaS was
stroke (n!842 patients), 573 of whom were diagnosed with
ischemic stroke, 220 with transient ischemic attack, and 49
with intracranial hemorrhage (33 and 16 patients with intra-
cerebral or subarachnoid hemorrhage, respectively). One
hundred fifty-three patients were included for unexplained
white matter lesions on neuroimaging but only 2 patients for
vertebrobasilar dolichoectasia. Specification of the inclusion
criterion was missing on the web-based inclusion form for 3
patients.
Evidence of acute cerebral infarction was present on
neuroimaging in 570 patients with ischemic stroke (99.5%).
The infarct was located in the anterior circulation in 335
patients (58.8%), in the posterior circulation in 152 patients
(26.7%), and in both the anterior and posterior circulation in
83 patients (14.6%). Stroke etiology was classified according
to TOAST criteria19 as atherothrombotic in 143 patients
(25.1%), cardioembolic in 125 (21.9%), and lacunar in 99
(17.4%). A specific cause for the ischemic stroke was present
in 69 patients (12.1%): cervicocephalic arterial dissection
(n!37), vasculitis (n!11), hereditary coagulopathy (n!6),
antiphospholipid syndrome (n!3), radiotherapy-induced vas-
culopathy (n!2), amphetamine-induced vasculopathy (n!2),
moyamoya syndrome (n!2), migrainous stroke (n!2), cere-
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bral venous thrombosis (n!2), hemolytic uremic syndrome
(n!1), and paraneoplastic coagulopathy (n!1). In 134 pa-
tients (23.5%), stroke etiology was cryptogenic. The preva-
lence of intracranial hemorrhage in the reported population
was only 5.8% of all stroke patients. This may be explained
by the fact that for patients with intracranial hemorrhage,
routine medical practice in many participating centers is often
provided by neurosurgeons rather than neurologists. Sixteen
of 49 patients with intracranial hemorrhage (32.7%) had
subarachnoid hemorrhage. The location of intracerebral hem-
orrhage was lobar in 13 patients (39.4%), involved basal
ganglia in 11 (33.3%), brain stem in 5 (15.2%), and thalamus
in 4 (12.1%). A cerebral vascular anomaly was present in 21
patients (aneurysm, cavernous malformation, and arterio-
venous malformation, respectively, in 15, 4, and 2 patients).
Other causes of intracranial hemorrhage included alcohol
abuse in 2 patients and hypertension in 1 individual. Unex-
plained white matter lesions and dolichoectasia were found in
patients who underwent neuroimaging for indications like
headache, dizziness, seizures, or syncope. Table 1 shows
baseline clinical data and signs and symptoms of Fabry
disease, according to the inclusion criterion. In contrast to
patients who were enrolled because of unexplained white
matter lesions, stroke patients were predominantly male, less
frequently received magnetic resonance–based neuroimag-
ing, displayed more classic cerebrovascular risk factors, and
more often had hypertrophic cardiomyopathy and a positive
family history of stroke or myocardial infarction at a young
age. A detailed stratification of the study population by entry
condition, sex, age, and cerebrovascular history is presented
in Table 2.
Diagnostic Test Results
As shown in the Figure, !-GAL A activity was assessed on
dried blood spot in 545 of 547 male patients and was below
the normal cutpoint of 3.0 nmol/h per mL in 19 patients.
Exonic DNA sequencing of GLA was performed in all these
patients but failed to identify a mutation. Additionally, a
repeat dried blood spot was obtained for 9 patients; !-GAL A
activity was found to be normal in 7. However, in 1 patient,
a complete enzyme deficiency was observed, and a severe
deficiency (0.3 ng/h per mL) was found in another (Table 3).
GLA sequencing results were available for 448 of 453
female patients. Two and 3 samples were lost due to a
technical error or during shipment, respectively. A missense
mutation was identified in 8 unrelated female patients:


















Age at presentation, y 48.2 (9.0) 47.0 (9.3) 48.8 (7.9) 46.4 (9.8) 56.0 (2.8) 0.065
Male 350 (61.1%) 122 (55.5%) 122 (55.5%) 44 (28.8%) 1 (50.0%) "0.001
MRI-based neuroimaging 451 (78.7%) 182 (82.7%) 20 (40.8%) 147 (93.6%) 2 (100%) "0.001
Classic cerebrovascular risk
factors
Arterial hypertension 241 (42.1%) 91 (41.4%) 19 (38.8%) 34 (22.2%) 2 (100.0%) "0.001
Diabetes mellitus 72 (12.6%) 18 (8.2%) 1 (2.0%) 5 (3.3%) 1 (50.0%) "0.001
Dyslipidemia 235 (41.0%) 106 (48.2%) 6 (12.3%) 34 (22.2%) 1 (50.0%) "0.001
Smoking 353 (61.6%) 119 (54.1%) 31 (63.3%) 55 (36.0%) 1 (50.0%) "0.001
Coronary disease 48 (8.4%) 18 (8.2%) 2 (4.1%) 7 (4.6%) 1 (50.0%) 0.075
Signs and symptoms
suggestive of Fabry disease
White matter lesions 153 (26.7%) 31 (14.1%) 12 (24.5%) 153 (100.0%) 1 (50.0%) "0.001
Previous stroke 87 (15.2%) 44 (20.0%) 9 (18.4%) 21 (13.7%) 0 (0.0%) 0.442
Renal disease 26 (4.5%) 8 (3.6%) 3 (6.1%) 6 (3.9%) 0 (0.0%) 0.930
Hypertrophic cardiomyopathy 75 (13.1%) 34 (15.5%) 5 (10.2%) 6 (3.9%) 0 (0.0%) "0.001
Family history of stroke 103 (18.0%) 59 (26.8%) 6 (12.3%) 25 (16.3%) 1 (50.0%) 0.017
Family history of MI "60 y 69 (12.0%) 41 (18.6%) 4 (8.2%) 13 (8.5%) 1 (50.0%) 0.012
Family history of dialysis 8 (1.4%) 3 (1.4%) 1 (2.0%) 1 (0.7%) 0 (0.0%) 0.942
Cornea verticillata 0 (0%) 0 (0%) 0 (0%) 1 (0.7%) 0 (0.0%) 0.002
Angiokeratoma 7 (1.2%) 2 (0.9%) 0 (0%) 0 (0%) 0 (0.0%) 0.061
Dyshidrosis 24 (4.2%) 11 (5.0%) 6 (12.2%) 5 (3.3%) 0 (0.0%) 0.119
Pain episodes 23 (4.0%) 18 (8.2%) 2 (4.1%) 26 (17.0%) 1 (50.0%) "0.001
Acroparesthesia 54 (9.4%) 34 (15.5%) 8 (16.3%) 37 (24.2%) 0 (0.0%) "0.001
TIA indicates transient ischemic attack; MRI, magnetic resonance imaging; and MI, myocardial infarction.
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Asp313Tyr in 5, Ala143Thr in 2 subjects, and a novel
mutation, Ser126Gly, in 1 subject (Table 4). The presence of
the mutation was confirmed by repeating the exonic DNA
sequencing.
Discussion
Cerebral micro- and macroangiopathies are hallmarks of
Fabry disease.17,20 It is hypothesized that lipid deposits in
vascular endothelial and smooth muscle cells cause oxidative
stress, vascular dysfunction, vessel occlusion, and tissue
ischemia.21 These pathophysiological mechanisms are asso-
ciated with an increased risk of premature stroke, progressive
white matter lesions, and dolichoectasia as major clinical and
neuroimaging correlates.17 Recent literature data indicate that
stroke frequently occurs before the diagnosis of Fabry disease
has been made and in the absence of other key signs of this
disease.22
In contrast to the considerable number of studies on the
presence of Fabry disease in patients with renal or cardiac
disorders,4–11 only 2 studies reported on the prevalence of
Fabry disease with neurologic hallmarks for this condi-
tion.13,16 Both studies focused on young patients with cryp-
togenic stroke. In a large cohort of 721 patients diagnosed
with cryptogenic stroke, the prevalence of Fabry disease was
found to be as high as 4.9% in men and 2.4% in women.13 We
were unable, however, to reproduce this finding in a retro-
spective study of 103 cryptogenic stroke patients.16 Fabry
disease is associated with cerebral micro- and macroangiopa-
thy.17,20 Moreover, cardioembolic phenomena23 and coagu-
lopathy24 may be common in this disorder. Limiting screen-
ing for Fabry disease to patients without these conditions
might therefore induce selection bias. For this reason, inclu-
sion criteria in BeFaS were not restricted to patients pres-
enting with cryptogenic stroke. Other screening projects for
Fabry disease in ischemic stroke patients have recently been
finalized (M.A. Wozniak et al and M. Viana-Baptista et al;
personal communications) or are currently ongoing. Despite
being identified as relevant indicators for cerebral vasculopa-
thy in Fabry disease, epidemiologic studies in patients with
stroke of all causes, unexplained white matter lesions, or
dolichoectasia have not been done before. Assessment of the
clinical signs suggestive of Fabry disease was not performed
in a standardized manner and may limit generalizability of
these findings. For instance, the remarkably high prevalence
of acroparesthesia in our population may be secondary to
overreporting.
In the present study, deficient !-GAL A activity was
present in 3.5% of male patients, and a mutation in GAL was
found in 1.8% of female patients. Diagnosis of Fabry disease,
however, is not straightforward in all patients. The absence of
a mutation in all male patients with this enzyme deficiency
suggests that the dried blood spot analysis may have been
false-positive in some patients. However, repeat assessment
!-GAL A activity in a subset of 9 patients confirmed the
enzyme deficiency in a patient aged 49 years with ischemic
stroke secondary to carotid artery dissection and in another
patient aged 54 years with a cryptogenic transient ischemic
Table 2. Study Population Stratified by Entry Condition, Sex,






Stroke Male 49.2 (8.5) 81 (16.2%)
Female 46.0 (9.4) 59 (17.5%)
Ischemic stroke Male 49.6 (8.6) 52 (14.9%)
Female 45.9 (9.1) 35 (15.7%)
TIA Male 48.4 (8.2) 20 (16.4%)
Female 45.3 (10.3) 24 (24.5%)
Intracranial hemorrhage Male 47.6 (8.5) 9 (32.1%)
Female 50.4 (6.7) 0 (0.0%)
Unexplained white matter
lesions
Male 47.7 (9.3) 10 (22.7%)
Female 45.9 (10.0) 11 (10.1%)
Vertebrobasilar
dolichoectasia
Male 57.0 (0.0) 0 (0.0%)
Female 55.0 (0.0) 0 (0.0%)
TIA indicates transient ischemic attack.
Figure. Flowchart for the BeFaS.
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attack (cases 4 and 17, Table 3). Magnetic resonance imaging
showed acute cerebral ischemia in the anterior circulation in
both patients, and the family history was remarkable for
stroke in 1 patient. An atypical variant of Fabry disease
cannot be excluded in these patients, and additional diagnos-
tic assessments are ongoing. We found the Asp313Tyr
mutation in 5 female patients. This mutation has been
identified in classically affected males as the single muta-
tion25 or in the cis position with another missense muta-
tion.26,27 On the other hand, this mutation was also reported in
0.45% of normal X chromosomes, and in vitro studies favor
the classification of Asp 313Tyr as a polymorphism.27 The
mutation Ala143Thr has previously been reported in patients
with the late-onset variant of Fabry disease,5,15 but Ser126Gly
appears to be a novel mutation that may also be linked to
late-onset Fabry disease. The discovery of a previously
unreported mutation is not surprising, because most families
have a private mutation and new mutations are frequently
found with the diagnosis of an index case.28
Our results suggest that Fabry disease may play a role in up
to 1% of young patients presenting with cerebrovascular
disease. However, current knowledge on the complex patho-
genesis of this condition is incomplete and does not always
allow a definitive diagnosis in every patient, especially in
cases of late-onset Fabry disease. This illustrates the need for
additional basic and epidemiologic research. In an ongoing
research project, we are focusing on patients with abnormal
screening results identified in the BeFaS and aim to obtain
more certainty about the diagnosis of Fabry disease through
careful clinical, biochemical, and histological examinations.
In addition, studies with larger cohorts of high-risk patients
are ongoing and may help to formulate definite answers for
these patients.
Summary
We report on a national, prospective, multicenter study on the
prevalence of Fabry disease in 1000 young patients pres-














1 60 2.1 Normal 21.7 Intracerebral hemorrhage Hypertension Negative
2 48 2.7 Normal NA Ischemic stroke Cryptogenic Negative
3 42 1.1 Normal 29.1 Ischemic stroke Cryptogenic Negative
4 49 1.0 Normal 1.5 Ischemic stroke Carotid dissection Negative
5 45 0.0 Normal 26.5 Ischemic stroke Cryptogenic Negative
6 53 1.8 Normal 26.3 TIA Cardioembolic Negative
7 54 2.8 Normal NA Ischemic stroke Atherothrombotic Negative
8 48 1.8 Normal NA White matter lesions Cryptogenic Negative
9 54 0.8 Normal NA Intracerebral hemorrhage Hemangioma Negative
10 31 2.7 Normal 3.4 Ischemic stroke Cryptogenic Negative
11 54 2.0 Normal NA Ischemic stroke Atherothrombotic Stroke
12 49 0.0 Normal NA Ischemic stroke Cryptogenic Negative
13 39 0.0 Normal NA Ischemic stroke Cardioembolic Negative
14 55 0.0 Normal NA TIA Cryptogenic Negative
15 52 1.5 Normal NA TIA Cryptogenic Negative
16 55 1.6 Normal 34.0 TIA Cryptogenic Negative
17 54 0.0 Normal 0.0 TIA Cryptogenic Negative
18 46 1.6 Normal NA Ischemic stroke Cryptogenic Negative
19 59 3.0 Normal 7.0 TIA Cardioembolic Negative
NA indicates not available; TIA, transient ischemic attack.
Table 4. Diagnostic Assessments in 8 Female Patients With a Mutation in the GAL
Case Age, y Gene Sequencing Inclusion Criterion Etiology Cerebrovascular History
1 43 Asp313Tyr TIA Cryptogenic Negative
2 52 Asp313Tyr TIA Cryptogenic Negative
3 41 Asp313Tyr White matter lesions Cryptogenic Negative
4 35 Asp313Tyr White matter lesions Cryptogenic Negative
5 53 Asp313Tyr TIA Cryptogenic Stroke
6 43 Ala143Thr Ischemic stroke Carotid dissection Negative
7 51 Ala143Thr Ischemic stroke Carotid dissection Negative
8 41 Ser126Gly Ischemic stroke Cryptogenic Negative
TIA indicates transient ischemic attack.
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enting with cerebrovascular disease. Our results suggest that
!-GAL A deficiency may play a role in up to 1% of young
patients presenting with cerebrovascular disease. Although
the clinical relevance is not straightforward in all cases, these
findings suggest that atypical variants of Fabry disease with
late-onset cerebrovascular disease exist and that their genetic
background is poorly understood.
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